GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of “Moderate Buy” by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.18.

A number of equities research analysts recently commented on the company. KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Citigroup cut their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Wells Fargo & Company cut their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th.

GoodRx Price Performance

NASDAQ:GDRX opened at $4.41 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market cap of $1.69 billion, a P/E ratio of -147.00, a PEG ratio of 2.46 and a beta of 1.25. The company has a fifty day moving average price of $4.76 and a 200 day moving average price of $5.26. GoodRx has a one year low of $4.09 and a one year high of $9.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of GoodRx by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock worth $38,935,000 after purchasing an additional 460,753 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of GoodRx by 22.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock valued at $9,264,000 after purchasing an additional 369,553 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in GoodRx during the third quarter valued at $11,295,000. Clearbridge Investments LLC bought a new stake in GoodRx during the fourth quarter worth about $5,863,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of GoodRx by 38.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company’s stock worth $5,714,000 after acquiring an additional 342,781 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.